Class overview · Reviewed July 24, 2026
GLP-1s and sleep apnea: which one is actually FDA-approved
Four drugs get discussed as if they were interchangeable here. Only one carries an obstructive sleep apnea indication — and the one that does shares its molecule with one that doesn't.
The short answer
Zepbound (tirzepatide) is the only GLP-1-class medication FDA-approved to treat obstructive sleep apnea, approved in December 2024 for moderate-to-severe OSA in adults with obesity. Mounjaro, Wegovy and Ozempic are not approved for OSA. Mounjaro is the identical molecule to Zepbound, which is the clearest illustration of a rule that runs through this whole category: the FDA approves a product and an indication, not a molecule — and that label is what your insurer reads.
Key takeaways
- Only Zepbound (tirzepatide) is FDA-approved to treat obstructive sleep apnea — approved December 2024 for moderate-to-severe OSA in adults with obesity, the first and only prescription drug with that indication.
- Mounjaro is the identical molecule to Zepbound but carries a type 2 diabetes label and no OSA indication; Wegovy and Ozempic (semaglutide) have no OSA indication either.
- In SURMOUNT-OSA (NEJM, 2024, 52 weeks), tirzepatide cut the apnea-hypopnea index by about 27.4 events per hour versus about 4.8 on placebo in CPAP-naive patients.
- Eligibility keys off severity: an AHI of 5 or more is OSA, 15 or more is moderate, 30 or more is severe — the approved indication covers moderate-to-severe.
- The OSA indication can open coverage that a weight-loss prescription cannot, because many plans exclude weight-loss drugs as a category while covering treatment for a diagnosed condition.
- None of this replaces CPAP. The approval added a drug option; it did not retire the standard of care, and stopping CPAP is a sleep-clinician decision.
Approved for OSA, drug by drug
Zepbound (tirzepatide) — approved for OSA
Approved December 2024 for moderate-to-severe OSA in adults with obesity — the only drug in the class with this indication.
Mounjaro (tirzepatide) — not approved for OSA
The same molecule as Zepbound, but labeled for type 2 diabetes. No OSA indication, which is why the brand on the prescription matters more than the drug inside.
Wegovy (semaglutide) — not approved for OSA
Labeled for weight management. No OSA indication — any effect on breathing events would come indirectly through weight loss.
Ozempic (semaglutide) — not approved for OSA
Labeled for type 2 diabetes. No OSA indication.
What the trial actually measured
The approval rests on SURMOUNT-OSA, published in the New England Journal of Medicine in 2024. Over 52 weeks, tirzepatide reduced the apnea-hypopnea index — the count of breathing interruptions per hour of sleep — by roughly 27.4 events per hour, against roughly 4.8 events per hour on placebo, in patients not using CPAP.
That is a large effect on the number the diagnosis is built from, which is why the indication exists at all rather than the drug simply being described as helpful for weight. What the trial did not test is stopping CPAP in people already using it — so it supports adding a treatment, not withdrawing one.
Where the severity line falls
OSA severity is graded by AHI, measured in a sleep study:
- AHI 5 or more — obstructive sleep apnea is present
- AHI 15 or more — moderate
- AHI 30 or more — severe
The approved indication is moderate-to-severe OSA in adults with obesity, so the practical threshold is generally an AHI of 15 or above with a documented sleep study. If you have never had one, that study is the gate for everything downstream — including the coverage argument below.
Why the indication is worth money, not just accuracy
Many plans exclude weight-loss drugs as a category. That exclusion is a purchasing decision, and no amount of medical evidence about weight moves it. A prescription to treat a diagnosed condition is a different request, and because Zepbound carries an approved OSA indication, documented moderate-to-severe OSA can be a route to coverage that a weight-loss prescription cannot reach.
It is not automatic. Expect prior authorization, expect the sleep study to be required documentation, and confirm the criteria with your own plan before assuming either answer. The brand-specific version of this, including what plans typically ask for, is in the Zepbound sleep apnea guide, and the prior-auth mechanics are in Zepbound prior authorization.
Do not change CPAP use on your own
CPAP remains the standard of care for obstructive sleep apnea. A drug approval added an option; it did not retire the device. Whether CPAP settings or use should change is a decision for the sleep clinician managing your diagnosis, normally based on a repeat sleep study — not on weight loss alone. This page is general information, not medical advice.
Compare providers that prescribe tirzepatide
SponsoredAn OSA diagnosis changes which prescription — and which coverage argument — is available to you. These are US-licensed providers ranked on total monthly cost; we compare and link, we never sell medication.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
Common questions about GLP-1s for sleep apnea
Do GLP-1 medications treat sleep apnea?
One does, as an approved treatment. Zepbound (tirzepatide) was approved by the FDA in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity — the first and only prescription medicine carrying that indication. Other GLP-1-class drugs, including Mounjaro, Wegovy and Ozempic, are not approved for OSA, so any benefit they produce would be indirect, through weight loss, rather than an approved treatment effect.
Is Mounjaro approved for sleep apnea if it is the same drug as Zepbound?
No. Mounjaro and Zepbound are both tirzepatide, but they are separate products with separate labels — Mounjaro for type 2 diabetes, Zepbound for weight management and, since December 2024, moderate-to-severe OSA. The FDA approves a product and an indication, not a molecule in the abstract, so only the Zepbound label carries OSA.
How much did tirzepatide reduce apnea events in the trial?
In SURMOUNT-OSA, published in NEJM in 2024, tirzepatide reduced the apnea-hypopnea index by roughly 27.4 events per hour at 52 weeks in CPAP-naive patients, compared with roughly 4.8 events per hour on placebo. AHI counts breathing interruptions per hour of sleep, so a drop of that size can move someone across severity categories.
What AHI do you need to qualify for GLP-1 treatment of sleep apnea?
The approved indication is moderate-to-severe OSA in adults with obesity. On the standard scale an AHI of 5 or more indicates OSA, 15 or more is moderate, and 30 or more is severe — so moderate-to-severe generally means an AHI of 15 or above, established by a sleep study. Your prescriber and sleep clinician apply the criteria to your specific results.
Can I stop using CPAP if I start a GLP-1?
Not on your own. CPAP remains the standard of care, and the approval added a drug option rather than replacing it. Any change to CPAP use is a decision for the sleep clinician managing your diagnosis, based on a repeat sleep study rather than on weight change alone.
Will insurance cover a GLP-1 for sleep apnea when it excludes weight-loss drugs?
Sometimes, and it is the practical reason the indication matters. Many plans exclude weight-loss drugs as a category but will consider a drug prescribed to treat a diagnosed condition. Because Zepbound carries an approved OSA indication, a prescription written for documented moderate-to-severe OSA is a different request than one written for weight loss. Coverage still varies by plan and usually requires prior authorization plus the sleep-study documentation, so confirm the criteria with your own plan.